Cargando…

PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies

Pancreatic cancer is the seventh leading cause of death in developed countries and it still has a poor prognosis despite intense research in the last 20 years. Immunotherapy is a relatively new strategy in cancer treatment. The aim of immunotherapy is to block the immunosuppressive effect of tumoral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mucileanu, Adrian, Chira, Romeo, Mircea, Petru Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iuliu Hatieganu University of Medicine and Pharmacy 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389876/ https://www.ncbi.nlm.nih.gov/pubmed/36105495 http://dx.doi.org/10.15386/mpr-2116

Ejemplares similares

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy
por: Mauzo, Shakuntala H., et al.
Publicado: (2019)

Mediastinal masses—transthoracic ultrasonography aspects
por: Chira, Romeo Ioan, et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Diagnostic yield of endoscopic ultrasound-guided biopsy of focal liver lesions
por: Ichim, Vlad Andrei, et al.
Publicado: (2019)

Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer
por: Karsono, Ramadhan, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

PD-L1(ATTAC) mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy
por: Fueyo-Marcos, Elena, et al.
Publicado: (2023)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer
por: Kim, Yeorae, et al.
Publicado: (2023)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
por: Raza, Afsheen, et al.
Publicado: (2023)

The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products
por: Bailly, Christian
Publicado: (2020)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
por: Ai, Leilei, et al.
Publicado: (2020)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
por: Xue, Chunyan, et al.
Publicado: (2019)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
por: Liu, Lingyue, et al.
Publicado: (2022)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_11mdr3g2f0gcl0o007qvkubrh8